The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
The biological activity of ab116171 is determined by its ability to inhibit Wnt3a induced alkaline phosphatase production in MC3T3-E1 cells. The expected ED50 for this effect is 40-60 ng/ml.
< 0.100 Eu/µg
% SDS-PAGE. The purity of ab116171 is greater than 80% by SDS-PAGE gel and HPLC analyses.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Store at -20ºC.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Reconstitute to a concentration of 0.1 mg/ml.
Protein Wnt-7a precursor
Proto oncogene Wnt7a protein
proto-oncogene wnt7a protein
wingless-type MMTV integration site family, member 7A
Wnt family member 7A
Ligand for members of the frizzled family of seven transmembrane receptors. Probable developmental protein. Signaling by Wnt-7a allows sexually dimorphic development of the mullerian ducts.
Expression is restricted to placenta, kidney, testis, uterus, fetal lung, and fetal and adult brain.
Involvement in disease
Defects in WNT7A are the cause of limb/pelvis-hypoplasia/aplasia syndrome (LPHAS) [MIM:276820]; also known as absence of ulna and fibula with severe limb deficiency. LPHAS is a limb-malformation disorder characterized by various degrees of limb aplasia/hypoplasia and joint dysplasia. Defects in WNT7A are a cause of Fuhrmann syndrome (FUHRS) [MIM:228930]; also known as fibular aplasia or hypoplasia femoral bowing and poly- syn- and oligodactyly. Fuhrmann syndrome is a distinct limb-malformation disorder characterized also by various degrees of limb aplasia/hypoplasia and joint dysplasia.
Belongs to the Wnt family.
Secreted > extracellular space > extracellular matrix.